Supplementary Fig. 1. Protocol design. IFX (10 mg/kg) was infused intravenously every 8 weeks until week 56 or the end of the study (discontinuation). The dosage of ED (900–1200 kcal/day), determined by the examining physician at the time of main registration, was administered daily until week 56. After obtaining informed consent from the patient, the preliminary registration was carried out. At 5 to 8 weeks after the last IFX administration, and after confirming eligibility, the patients were enrolled and observed until week 56. IFX, infliximab; ED, elemental diet.